SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Kanner AM. Curr. Pain Headache Rep. 2011; 15(3): 164-169.

Copyright

(Copyright © 2011, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s11916-011-0199-x

PMID

21479999

Abstract

Three antiepileptic drugs (AEDs), valproic acid, gabapentin, and topiramate (TPM), are used frequently in the prophylactic treatment of migraines. In December 2008, the US Food and Drug Administration issued a warning suggesting that the use of all AEDs is associated with an increased risk of suicidal ideation and behavior. This warning has been received by the medical community with great skepticism, and the validity of the findings of the meta-analysis that led to its publication has been questioned because of various methodological problems. Yet, migraine by itself is associated with an increased risk of suicidal ideation and behavior as well as with an increased risk of psychiatric disorders that facilitate the development of suicidal behavior. Furthermore, TPM has been associated with psychiatric adverse events that potentially could result in suicidal ideation and behavior. In this article, we review data to determine whether the AEDs used in the prevention of migraine are associated with an increased risk of suicidality.


Language: en

Keywords

Humans; Risk Factors; United States; Suicide; Treatment Outcome; Suicidal Ideation; United States Food and Drug Administration; Gabapentin; Anticonvulsants; Migraine Disorders; Topiramate; gamma-Aminobutyric Acid; Valproic Acid; Drug Labeling; Amines; Cyclohexanecarboxylic Acids; Fructose

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print